-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the State Medical Products Administration approved the listing of the new compound preparation of traditional Chinese medicine Qi Jiao Jingjing granules declared by Hunan Anbang Pharmaceutical Co.
, Ltd.
The drug is composed of 9 flavored medicines such as astragalus, ejiao, codonopsis, white peony, etc.
, which has the effect of invigorating qi and replenishing blood, stopping bleeding and regulating menstruation, and is used for the prolongation of menstruation caused by the upper ring, and the differentiation of traditional Chinese medicine is the two deficiency of
qi and blood.
, Ltd.
The drug is composed of 9 flavored medicines such as astragalus, ejiao, codonopsis, white peony, etc.
, which has the effect of invigorating qi and replenishing blood, stopping bleeding and regulating menstruation, and is used for the prolongation of menstruation caused by the upper ring, and the differentiation of traditional Chinese medicine is the two deficiency of
qi and blood.
The drug has carried out multi-center, randomized, double-blind, marketed parallel controlled clinical trials of traditional Chinese
medicines.
The results of clinical trial studies showed that the recovery rate and the pronounced rate were 31.
82% and 63.
64% in the experimental group and 12.
00% and 38.
00% in the control group, respectively.
The launch of the drug will provide new treatment options
for patients with clinically relevant diseases.
medicines.
The results of clinical trial studies showed that the recovery rate and the pronounced rate were 31.
82% and 63.
64% in the experimental group and 12.
00% and 38.
00% in the control group, respectively.
The launch of the drug will provide new treatment options
for patients with clinically relevant diseases.
